ICER Report on Eliquis, Xarelto May Aid Drug Price Negotiations
October
12
The Institute for Clinical and Economic Review (ICER) published a report on Oct. 2 evaluating the blood thinners Eliquis (apixaban) and Xarelto (rivaroxaban), two of the 10 drugs that will be subject to Medicare price negotiations starting in 2026.
Based on ICER’s modeling and review of the available evidence, the organization determined that Eliquis and Xarelto could have substantial price premiums over warfarin. However, when compared with dabigatran, ICER noted that Eliquis could have a smaller price premium and Xarelto could have no price premium. Warfarin and dabigatran are both generic drugs that are competitors to Eliquis and Xarelto.
© 2023 MMIT
Related Posts
September
1
Medicare Drug Price Negotiation: ‘Spillover Effect’ on Private Market Remains Fuzzy
READ MORE
September
1
Majority of Drugs Selected for Price Negotiation Are on ‘Preferred’ Tiers in Medicare
READ MORE
August
24
Drugmakers Already Offer Big Rebates for Some Meds Likely to Face Medicare Negotiation
READ MORE
Meet Our Reporters
-
Lauren Flynn Kelly Executive Editor, AIS Health, and Managing Editor, Radar on Medicare Advantage
View Lauren Flynn Kelly's Profile -
Angela Maas Managing Editor, Radar on Specialty Pharmacy and Spotlight on Market Access
View Angela Maas's Profile -
Leslie Small Managing Editor, Health Plan Weekly and Radar on Drug Benefits
View Leslie Small's Profile -
Peter Johnson Reporter, Health Plan Weekly and Radar on Drug Benefits
View Peter Johnson's Profile -
Tim Casey Reporter, Health Plan Weekly and Radar on Drug Benefits
View Tim Casey's Profile -
Carina Belles Reporter, Radar on Medicare Advantage and Spotlight on Market Access
View Carina Belles's Profile -
Jinghong Chen Reporter, Health Plan Weekly and Radar on Drug Benefits
View Jinghong Chen's Profile